MA41140A - Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg - Google Patents
Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la pargInfo
- Publication number
- MA41140A MA41140A MA041140A MA41140A MA41140A MA 41140 A MA41140 A MA 41140A MA 041140 A MA041140 A MA 041140A MA 41140 A MA41140 A MA 41140A MA 41140 A MA41140 A MA 41140A
- Authority
- MA
- Morocco
- Prior art keywords
- quinazoline
- dioxo
- sulfonamide derivatives
- parg inhibitors
- parg
- Prior art date
Links
- KAWUVVGXVHQMKP-UHFFFAOYSA-N 2,4-dioxo-1h-quinazoline-6-sulfonamide Chemical class N1C(=O)NC(=O)C2=CC(S(=O)(=O)N)=CC=C21 KAWUVVGXVHQMKP-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422098 | 2014-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41140A true MA41140A (fr) | 2017-10-17 |
Family
ID=54937266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041140A MA41140A (fr) | 2014-12-12 | 2015-12-10 | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10239843B2 (fr) |
| EP (1) | EP3230273A1 (fr) |
| JP (1) | JP2017537137A (fr) |
| KR (1) | KR20170093967A (fr) |
| CN (1) | CN107207467A (fr) |
| AU (1) | AU2015359082A1 (fr) |
| BR (1) | BR112017012402A2 (fr) |
| CA (1) | CA2969296A1 (fr) |
| IL (1) | IL252575A0 (fr) |
| MA (1) | MA41140A (fr) |
| MX (1) | MX2017007478A (fr) |
| RU (1) | RU2017124425A (fr) |
| SG (1) | SG11201704686UA (fr) |
| WO (1) | WO2016092326A1 (fr) |
| ZA (1) | ZA201704382B (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| US9624219B2 (en) | 2015-04-21 | 2017-04-18 | Glaxosmithkline Intellectual Property Development Limited | Compound (S) and (R)-N-(2-fluoropyridin-4-yl)-3-methyl-2-(5-methyl-2,4-dioxo-1,2-dihydropyrido[3,4-d]pyrimidin-3(4H)-yl)butanamide and use |
| US20220389003A1 (en) * | 2019-09-20 | 2022-12-08 | Ideaya Biosciences, Inc. | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
| TW202241908A (zh) * | 2020-12-24 | 2022-11-01 | 日商模數探索股份有限公司 | 四氫噻吩并嘧啶磺醯胺化合物 |
| AU2022359801A1 (en) | 2021-10-04 | 2024-02-01 | Forx Therapeutics Ag | Parg inhibitory compounds |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| WO2024074497A1 (fr) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Composé inhibiteur de parg |
| US12227484B2 (en) | 2022-02-14 | 2025-02-18 | Arase Therapeutics Inc. | Inhibitors of PARG |
| CN116693519A (zh) | 2022-03-04 | 2023-09-05 | 上海璎黎药业有限公司 | 一种含五元杂芳环结构化合物、其药物组合物及应用 |
| WO2023175185A1 (fr) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer |
| WO2023175184A1 (fr) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés comme inhibiteurs de parg pour le traitement du cancer |
| AR128846A1 (es) | 2022-03-23 | 2024-06-19 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg |
| CA3250037A1 (fr) * | 2022-04-28 | 2023-11-02 | Danatlas Pharmaceuticals Co., Ltd. | Dérivés hétérocycliques tricycliques, compositions et utilisations de ceux-ci |
| TW202409036A (zh) * | 2022-05-17 | 2024-03-01 | 美商858療法股份有限公司 | Parg抑制劑 |
| JP2025522274A (ja) | 2022-05-17 | 2025-07-15 | ８５８ セラピューティクス，インコーポレーテッド | Ｐａｒｇの阻害剤 |
| CN119522220A (zh) * | 2022-07-19 | 2025-02-25 | 苏州信诺维医药科技股份有限公司 | 含硫杂芳环化合物、其药物组合物及其用途 |
| EP4311829A1 (fr) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Dérivés d'hétéroaryl sulfonamide bicyclique substitués pour le traitement du cancer |
| WO2024173524A1 (fr) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Composés benzimidazoles à substitution hétéroaryle |
| WO2024173514A1 (fr) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Composés d'imidazopyridine à substitution amide et ester |
| WO2024173453A1 (fr) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Composés d'imidazopyridine à substitution hétéroaryle |
| WO2024173530A1 (fr) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Composés pyrazolo/imidazo pyridine à substitution hétéroaryle |
| EP4688159A1 (fr) | 2023-04-05 | 2026-02-11 | FoRx Therapeutics AG | Composés inhibiteurs de parg |
| CN119143747A (zh) * | 2023-06-16 | 2024-12-17 | 上海璎黎药业有限公司 | 一种杂芳环结构化合物、其药物组合物及应用 |
| WO2025046148A1 (fr) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Nouveaux inhibiteurs de parg |
| TW202517256A (zh) * | 2023-09-14 | 2025-05-01 | 中國大陸商再鼎醫藥（上海）有限公司 | 稠合雙環雜芳基作為ｐａｒｇ抑制劑及其用途 |
| WO2025073870A1 (fr) | 2023-10-03 | 2025-04-10 | Forx Therapeutics Ag | Composé inhibiteur de parg |
| WO2025093755A1 (fr) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Nouveaux inhibiteurs de parg |
| WO2025111339A1 (fr) * | 2023-11-21 | 2025-05-30 | 858 Therapeutics, Inc. | Traitement du cancer avec un inhibiteur de parg |
| WO2025133396A1 (fr) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Nouveaux inhibiteurs de parg bicyclo hétéroaryles |
| WO2025165942A1 (fr) * | 2024-01-31 | 2025-08-07 | Synnovation Therapeutics, Inc. | Composés tricycliques utilisés en tant qu'inhibiteurs de parg |
| WO2025245087A1 (fr) * | 2024-05-23 | 2025-11-27 | Synnovation Therapeutics, Inc. | Composés hétérocycliques utilisés en tant qu'inhibiteurs de parg |
| WO2026022150A1 (fr) | 2024-07-22 | 2026-01-29 | Forx Therapeutics Ag | Composés inhibiteurs de parg |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1157858A (fr) * | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Derives de quinazoline |
| DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| ATE428714T1 (de) | 2004-02-24 | 2009-05-15 | Japan Tobacco Inc | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US20070032496A1 (en) * | 2005-07-26 | 2007-02-08 | Hergenrother Paul J | Compounds for the Treatment of Neurodegeneration and Stroke |
| HRP20130058T1 (hr) | 2006-01-24 | 2013-02-28 | Eli Lilly & Company | Indolsulfonamidni modulatori progesteronskih receptora |
| CA2645583A1 (fr) * | 2006-03-20 | 2007-09-27 | F. Hoffman-La Roche Ag | Procedes d'inhibition des proteines kinase btk et syk |
| US20100298289A1 (en) * | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| EP2298767A4 (fr) | 2008-07-17 | 2011-10-19 | Asahi Kasei Pharma Corp | Composé hétérocyclique bicyclique azoté |
| CN101429191B (zh) | 2008-11-03 | 2012-05-23 | 中国药科大学 | 取代的四氢异喹啉衍生物的用途 |
| JP2013526484A (ja) | 2010-05-07 | 2013-06-24 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのアミノ‐キノリン |
| JP5864546B2 (ja) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| EP2627648A1 (fr) * | 2010-09-16 | 2013-08-21 | Novartis AG | INHIBITEURS DE LA 17a-HYDROXYLASE/C17,20-LYASE |
| AR084280A1 (es) | 2010-12-17 | 2013-05-02 | Hoffmann La Roche | Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos |
| EP2471363A1 (fr) * | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Utilisation d'acides aryl-, hétéroaryl- et benzylsulfonaminés, d'esters d'acide aminé, d'amides d'acide aminé et carbonitrile ou leurs sels pour l'augmentation de la tolérance au stress dans des plantes |
| WO2013027168A1 (fr) * | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine |
| WO2013067300A1 (fr) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Méthode de traitement |
| JP2014106019A (ja) | 2012-11-26 | 2014-06-09 | Stack Electronics Co Ltd | プローブ |
| US9938236B2 (en) * | 2012-12-27 | 2018-04-10 | Drexel University | Antiviral agents against HBV infection |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
-
2015
- 2015-12-10 MA MA041140A patent/MA41140A/fr unknown
- 2015-12-11 CA CA2969296A patent/CA2969296A1/fr not_active Abandoned
- 2015-12-11 SG SG11201704686UA patent/SG11201704686UA/en unknown
- 2015-12-11 KR KR1020177019260A patent/KR20170093967A/ko not_active Withdrawn
- 2015-12-11 AU AU2015359082A patent/AU2015359082A1/en not_active Abandoned
- 2015-12-11 EP EP15813508.7A patent/EP3230273A1/fr not_active Withdrawn
- 2015-12-11 WO PCT/GB2015/053883 patent/WO2016092326A1/fr not_active Ceased
- 2015-12-11 BR BR112017012402A patent/BR112017012402A2/pt not_active Application Discontinuation
- 2015-12-11 MX MX2017007478A patent/MX2017007478A/es unknown
- 2015-12-11 JP JP2017531303A patent/JP2017537137A/ja active Pending
- 2015-12-11 RU RU2017124425A patent/RU2017124425A/ru not_active Application Discontinuation
- 2015-12-11 US US15/533,804 patent/US10239843B2/en active Active
- 2015-12-11 CN CN201580075728.3A patent/CN107207467A/zh active Pending
-
2017
- 2017-05-29 IL IL252575A patent/IL252575A0/en unknown
- 2017-06-28 ZA ZA2017/04382A patent/ZA201704382B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10239843B2 (en) | 2019-03-26 |
| SG11201704686UA (en) | 2017-07-28 |
| KR20170093967A (ko) | 2017-08-16 |
| ZA201704382B (en) | 2019-09-25 |
| AU2015359082A1 (en) | 2017-06-29 |
| IL252575A0 (en) | 2017-07-31 |
| CA2969296A1 (fr) | 2016-06-16 |
| MX2017007478A (es) | 2018-05-04 |
| CN107207467A (zh) | 2017-09-26 |
| RU2017124425A (ru) | 2019-01-14 |
| BR112017012402A2 (pt) | 2017-12-26 |
| US20180016242A1 (en) | 2018-01-18 |
| EP3230273A1 (fr) | 2017-10-18 |
| JP2017537137A (ja) | 2017-12-14 |
| WO2016092326A1 (fr) | 2016-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg | |
| MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
| HUE058009T2 (hu) | 1,3-Tiazol-2-il szubsztituált benzamid-származékok | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| LT3190113T (lt) | Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| DK3319956T3 (da) | Substituerede oxopyridinderivater | |
| MA40943A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA40940A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| DK3094631T3 (da) | Pyrimidinyloxybenzenderivater som herbicider | |
| IL252089A0 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| DK3253762T3 (da) | 9h-pyrrolo-dipyridinderivater. | |
| EP3457851A4 (fr) | Dérivés de sobétirome | |
| EP3283171A4 (fr) | Dérivés d'amphotéricine b | |
| IL250038A0 (en) | 4,5 - dehydroisoxazole derivatives used as nampt inhibitors | |
| DK3153508T3 (da) | Naphthofuranderivater til anvendelse som anticancermidler | |
| LT3273947T (lt) | Kompozicija, skirta akių sveikatai | |
| EP2953470A4 (fr) | Purines 2,6,7 substituées utilisées en tant qu'inhibiteurs de hdm2 | |
| SMT202200179T1 (it) | Composizione acquosa oftalmica. | |
| LT3347360T (lt) | Junginiai, naudingi ror-gama-t slopinimui | |
| IL260011A (en) | History of 5,3-diphenyl-diazole water-soluble compounds | |
| LT3341380T (lt) | Chromono oksimo darinys, prasiskverbiantis į smegenis, skirtas levadopa sukeltos diskinezijos gydymui | |
| LT3389633T (lt) | Farmacinės kompozicijos, apimančios fenilaminopirimidino darinį | |
| DK3319970T3 (da) | Pyrido-oxazinonderivater som tnap-hæmmere |